Primary analysis |
|
|
Composite (univariate) ‡
|
1.002 (0.999–1.005)
|
.24
|
Composite outcome (multivariable) ‡
|
1.002 (0.999–1.005)
|
.16
|
Age (per 5-year increase)
|
0.995 (0.992–0.998)
|
<.001
|
Sex (male)
|
1.002 (0.999–1.005)
|
.15
|
Asthma/chronic lung disease
|
1.059 (1.056–1.063)
|
<.001
|
Metabolic/endocrine disorder
|
1.021 (1.010–1.031)
|
<.001
|
Neurological condition
|
1.025 (1.015–1.035)
|
<.001
|
Heart disease
|
1.013 (1.002–1.024)
|
.020
|
Blood disease
|
1.016 (1.005–1.027)
|
.002
|
Secondary outcome§ |
|
|
Hospitalization‡
|
1.000 (1.000–1.000)
|
.77
|
Laboratory test‡
|
1.000 (0.998–1.003)
|
.78
|
Imaging‡
|
1.000 (0.999–1.002)
|
.16
|
Antibiotics use‡
|
1.000 (0.998–1.002)
|
.67
|
Return visit‡, ¶
|
1.005 (0.999–1.011) |
.082 |
Subgroup analysis |
|
|
Oseltamivir‡
|
1.011 (1.007–1.015)
|
<.001
|
Laninamivir‡
|
0.999 (0.996–1.003)
|
.81
|
Zanamivir‡
|
0.995 (0.991–0.999)
|
.039
|